Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer With Bone Metastases

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-1269
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Treatment of Castration-Resistant Prostate Cancer and Bone Metastases With Radium-223 Dichloride

International Journal of Urological Nursing
UrologyNursingNephrology
2014English

The Α-Receptor for Platelet-Derived Growth Factor as a Target for Antibody-Mediated Inhibition of Skeletal Metastases From Prostate Cancer Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2008English

Radium-223 for the Treatment of Patients With Castration-Resistant Prostate Cancer With Bone Metastases

Medical Council
2018English

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

Journal of the Advanced Practitioner in Oncology
2015English

The -Receptor for Platelet-Derived Growth Factor Confers Bone-Metastatic Potential to Prostate Cancer Cells by Ligand- And Dimerization-Independent Mechanisms

Cancer Research
Cancer ResearchOncology
2010English

Platelet Derived Growth Factor a (PDGFA; PDGF1); Platelet Derived Growth Factor Receptor (PDGFR)

Science-Business eXchange
2011English

Androgen Receptor Inhibitor–induced “BRCAness” and PARP Inhibition Are Synthetically Lethal for Castration-Resistant Prostate Cancer

Science Signaling
BiochemistryCell BiologyMolecular Biology
2017English

Effect of Platelet-Derived Growth Factor Receptor-Β Inhibition With STI571 on Radioimmunotherapy

Cancer Research
Cancer ResearchOncology
2005English

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling

PLoS ONE
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy